Oragenics, Inc. provided a corporate update on October 9, 2024, reflecting on its progress throughout 2024, including key milestones for ONP-002. The company strengthened its clinical leadership by appointing Dr. James Kelly as Chief Medical Officer and Dr. William Peacock as Chief Clinical Officer.
Operational advancements in 2024 included ONP-002 demonstrating stability across a wide temperature range, eliminating the need for cold-chain storage. The company also completed the spray-dry formulation of ONP-002 and filled intranasal delivery devices for the upcoming Phase II trial.
A novel nanoparticle spray-dried powder formulation was created, designed to enhance intranasal absorption and increase the amount of ONP-002 per dose by four-fold. These developments aim to improve drug delivery and increase the chance of reaching therapeutic levels in the brain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.